Radiopharm Theranostics Ltd 6-K Filing
Ticker: RDPTF · Form: 6-K · Filed: Dec 4, 2025 · CIK: 1949257
| Field | Detail |
|---|---|
| Company | Radiopharm Theranostics Ltd (RDPTF) |
| Form Type | 6-K |
| Filed Date | Dec 4, 2025 |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 6-K filing submitted by Radiopharm Theranostics Ltd (ticker: RDPTF) to the SEC on Dec 4, 2025.
How long is this filing?
Radiopharm Theranostics Ltd's 6-K filing is 1 pages with approximately 309 words. Estimated reading time is 1 minutes.
Where can I view the full 6-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 309 words · 1 min read · ~1 pages · Grade level 18.7 · Accepted 2025-12-03 21:27:18
Filing Documents
- ea0268437-6k_radio.htm (6-K) — 12KB
- ea026843701ex99-1_radio.htm (EX-99.1) — 18KB
- ex99-1_001.jpg (GRAPHIC) — 11KB
- ex99-1_002.jpg (GRAPHIC) — 8KB
- ex99-1_003.jpg (GRAPHIC) — 1KB
- 0001213900-25-118023.txt ( ) — 59KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Month of December 2025 Commission File Number: 001-41621 RADIOPHARM THERANOSTICS LIMITED (Name of Registrant) Level 3, 62 Lygon Street, Carlton South, Victoria, 3053, Australia (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes No If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- RADIOPHARM THERANOSTICS LIMITED EXPLANATORY NOTE Radiopharm Theranostics Limited (the “Company”) published an announcement (the “Public Notice”) to the Australian Securities Exchange on December 3, 2025 titled: “Results of Meeting” A copy of the Public Notice is attached as an exhibit to this report on Form 6-K. This report on Form 6-K (including the exhibit hereto) shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing. 1 EXHIBITS Exhibit Number Description 99.1 Results of Meeting 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. RADIOPHARM THERANOSTICS LIMITED Date: December 3, 2025 By: /s/ Phillip Hains Phillip Hains Company Secretary 3